| Interacting proteins: P35237 and P00749 |
Pubmed |
SVM Score :0.0 |
| This sequence is located between positions 179 and 158 upstream of the cap site and is known to contain an activating transcription factor ( ATF ) binding site . ^^^ |
|
| Interacting proteins: P35237 and P00749 |
Pubmed |
SVM Score :0.0 |
| Urokinase type plasminogen activator ( u PA ) contributes to tumor progression in prostate cancer ( CaP ) . ^^^ However , signaling pathways mediating u PA gene expression in CaP are not delineated . ^^^ We hypothesized that MAPK pathways mediate u PA in CaP , and thereby studied specific ERK , JNK , and P 38 MAPK pathway mutant constructs and inhibitors in vitro . ^^^ Collectively , these results show that MAPK pathways ERK , JNK / SAPK , and P 38 MAPK represent a significant component in the regulation of u PA expression in human CaP . . ^^^ Urokinase type plasminogen activator ( u PA ) contributes to tumor progression in prostate cancer ( CaP ) . ^^^ |
|
| Interacting proteins: P35237 and P00749 |
Pubmed |
SVM Score :0.0 |
| Regulation of u PA gene expression in human prostate cancer . u PA contributes to CaP progression , especially in the metastatic androgen insensitive state . ^^^ In vitro , u PA is expressed by androgen insensitive , but not androgen sensitive , CaP cell lines . ^^^ We hypothesized that in androgen sensitive CaP an activated ARE represses u PA expression but in androgen insensitive CaP this repression is lost and u PA is upregulated through MAP kinase signaling pathways . ^^^ To determine whether binding of the DHT AR complex to AREs in the u PA promoter region represses u PA transcription in androgen sensitive CaP , we studied 2 PC 3 androgen insensitive human CaP cell lines stably transfected with AR [ PC 3 ( AR ) ( 2 ) and PC 3 ( AR ) ( 13 ) ] and 1 mock transfected cell line [ PC 3 ( M ) ] . ^^^ To explore the pathway stimulating u PA expression in CaP , we performed transient transfections in PC 3 ( AR ) ( 2 ) cells using u PA promoter regulated CAT reporter constructs . ^^^ |
|
| Interacting proteins: P35237 and P00749 |
Pubmed |
SVM Score :0.0 |
| PURPOSE : To quantify the ex vivo production of proangiogenic proteins ( vascular endothelial growth factor ( VEGF ) , basic fibroblast growth factor ( bFGF ) , urokinase type plasminogen activator ( u PA ) , tissue type plasminogen activator ( tPA ) ) and angiogenesis inhibitors ( plasminogen activator inhibitor type 1 ( PAI 1 ) and angiostatin ) from epithelial and stromal components of primary prostate cancer ( CaP ) and benign prostatic hyperplasia ( BPH ) cultures . ^^^ |
|
| Interacting proteins: P35237 and P00749 |
Pubmed |
SVM Score :0.0 |
| The survival rates of the patients were calculated and the prognostic values for u PA content ( less than 8 ng / mg protein versus more than 8 ng / mg ) , Stage ( pTa or pT 1 ) , grade ( 1 and 2 versus 3 ) , number ( single versus multiple ) , and size ( less than 1 cm versus more than 1 cm ) of tumor were determined by a multivariate regression model . ^^^ |
|
| Interacting proteins: P35237 and P00749 |
Pubmed |
SVM Score :0.0 |
| Cellular accumulation of uPA PAI 1 [ correction of UPA PAI 1 ] and uPA PAI 2 [ correction of UPA PAI 2 ] complexes in early ( pT 1 ) breast cancer : a new link in the uPA UPAr PAI chain . ^^^ OBJECTIVE : To investigate the role of uPA in early ( pT 1 ) breast cancer . ^^^ |
|
| Interacting proteins: P35237 and P00749 |
Pubmed |
SVM Score :0.0 |
| The PTF / ATF was analyzed as the water perfusable tissue index ( PTI ) . ^^^ |
|
| Interacting proteins: P35237 and P00749 |
Pubmed |
SVM Score :0.0 |
| RESULTS : The PTI ( =PTF / ATF ) was reduced in DCM compared with control subjects ( 0 . 91 + / 0 . 12 vs . 1 . 12 + / 0 . 10 ; P < 0 . 01 ) . ^^^ |
|
| Interacting proteins: P35237 and P00749 |
Pubmed |
SVM Score :0.0 |
| Using this technique , we have studied a series of 212 early ( pT 1 ) unifocal breast cancers and have correlated the expression of uPA PAI 1 complexes , together with other clinical and biological features ( histologic variety , histologic and nuclear grade , hormone receptors , Ki 67 labelling index , c erb B 2 , p 53 and CD44std expression ) with or without the occurrence of axillary node invasion . ^^^ |
|
| Interacting proteins: P35237 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35237 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35237 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35237 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35237 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35237 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35237 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35237 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35237 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35237 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35237 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35237 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35237 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35237 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35237 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35237 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35237 and P00749 |
Pubmed |
SVM Score :0.0 |
| NA |
|